The muscle aches you feel on a cholesterol pill are real — but in most cases the pill is not what caused them. That is not a polite way of doubting you. It is the result of clinical trials that gave people months of a statin and months of an identical dummy capsule without anyone knowing which was which — and the symptoms turned up at almost exactly the same rate either way. The practical lesson matters more than the surprise: the symptom is one question, the cause is a completely different one, and only a trial in which you do not know what you are swallowing can answer the second.
This article is educational only and is not a substitute for your doctor's advice. Do not start, stop, or change the dose of any medicine based on what you read here.
What does a statin actually do — and why isn't it prescribed on a number alone?
Statins work in a direct, well-understood way. In Cleveland Clinic's words, they "don't let your liver have an enzyme (HMG-CoA reductase) it needs to create cholesterol." The target is not cholesterol absorption from food; it is the production line inside the liver itself. And the effect is powerful: "Some statins can decrease your LDL cholesterol by 50% or more."
But the more important point is not how hard they push the number down. It is why they get prescribed at all. A statin is not prescribed because a figure on a lab report is high; it is prescribed because your estimated cardiovascular risk is high. That is explicit in the U.S. Preventive Services Task Force statement of 23 August 2022: a grade B recommendation for adults aged 40 to 75 with one or more CVD risk factors and "an estimated 10-year risk of 10% or greater"; a weaker grade C — offer selectively — for those whose risk is "7.5% to less than 10%"; and a grade I, meaning the evidence is insufficient to assess benefits and harms, for "adults 76 years or older."
Look at what that implies. Two people with the identical number on a lab slip may differ in whether the drug is worth taking, because the rest of the picture differs — age, blood pressure, smoking, diabetes. So "is my cholesterol high?" is an incomplete question. The complete one is "what is my risk?" We have written before about how the standard lipid panel leaves two important numbers out of that picture entirely — this is another instalment of the same idea.
How big is the benefit in absolute terms, not relative ones?
This is where most public argument about statins goes wrong. The systematic review prepared by Chou R, Cantor A, Dana T, Wagner J, Ahmed A, Fu R and Ferencik M for the Task Force (Evidence Synthesis No. 219, February 2022, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University) pooled 22 trials with 90,624 participants in primary prevention, and reported the benefit both ways at once:
- All-cause mortality: relative risk 0.92 (95% CI 0.87 to 0.98); absolute risk difference −0.35%; number needed to treat 286.
- Stroke: 0.78 (0.68 to 0.90); absolute difference −0.39%; NNT 256.
- Myocardial infarction: 0.67 (0.60 to 0.75); absolute difference −0.84%; NNT 119.
- Composite cardiovascular outcome: 0.72 (0.64 to 0.81); absolute difference −1.28%; NNT 78.
"A 33% reduction in heart attacks" and "an absolute difference of 0.84%" describe the same result. The first sounds like a revolution and the second sounds like a rounding error, and both are true — the distance between them is your baseline risk. That is exactly why the drug's value climbs as your risk climbs and falls as your risk falls, and exactly what those graded recommendations above are encoding.
The accusation and the blinded trial: what happens when you don't know what you're taking?
Here is the spine of the matter. The problem with linking "I started the drug" to "the aching started" is that the comparison has no witness. Nobody knows how your body would have felt in that same month on nothing at all, or on a capsule containing no drug. Two trials were designed to close precisely that gap.
SAMSON: twelve bottles, four of them empty
In the SAMSON trial (Howard JP, Wood FA, Finegold JA, Nowbar AN and colleagues, Journal of the American College of Cardiology 2021;78(12):1210–1222), 60 people who had already stopped statins because of side effects were randomised, and 49 completed the protocol. Each received twelve monthly bottles: four containing atorvastatin 20 mg, four containing placebo, and four completely empty. Every day they rated symptom intensity in an app on a scale of 1 to 100.
The result:
- In the no-tablet months: mean symptom score 8.0.
- In the statin months: 16.3 (P < 0.001 versus no-tablet months).
- In the placebo months: 15.4 (P < 0.001 as well).
In other words, symptoms roughly doubled on the act of taking a tablet — not on taking a drug. The trial calculated what it called the nocebo ratio, and it came out at 0.90. Harvard Health put the same finding in plain words: "90% of the symptoms people recorded when taking statins were also present when they took the placebo." Stopping a bottle early "was no more frequent for statin than placebo (P = 0.173)." And the figure that matters most in practice: at six months, "30 of 60 (50%) participants were back taking statins."
A definition is needed here, because the word does a lot of work. The nocebo effect is, as Harvard Health describes it, "the opposite of the placebo effect; with the nocebo effect, people who have negative expectations about medicine or a treatment experience harmful symptoms they otherwise wouldn't have." It is not pretending and it is not weakness. It is pain that is genuinely felt, arising from expectation rather than from the molecule.
StatinWISE: 200 people who had already had the symptoms
The natural objection to SAMSON is its size. Which is why StatinWISE matters (Herrett E, Williamson E, Brack K and colleagues, BMJ 2021;372:n135). It ran across 50 primary care sites in the United Kingdom between December 2016 and April 2018, in 200 participants who "had recently stopped or were considering stopping treatment with statins because of muscle symptoms" — the hardest possible group, not healthy volunteers. Each was randomised to "a sequence of six double blinded treatment periods (two months each) of atorvastatin 20 mg daily or placebo," rating muscle symptoms at the end of each period on a 0-to-10 visual analogue scale.
151 participants supplied scores usable for the primary analysis, and the finding was, verbatim: "Overall, no difference in muscle symptom scores was found between the statin and placebo periods (mean difference statin minus placebo −0.11, 95% confidence interval −0.36 to 0.14; P=0.40)." Withdrawals because of intolerable muscle symptoms were "18 participants (9%) during a statin period and 13 (7%) during a placebo period." The authors concluded: "No overall effect of atorvastatin 20 mg on muscle symptoms compared with placebo was found in participants who had previously reported severe muscle symptoms when taking statins." And "two thirds of those completing the trial reported restarting long term treatment with statins."
And the limits of both trials, in the investigators' own words
Honesty means carrying the caveats, not just the headline. The StatinWISE team noted that only 151 of 200 participants provided enough data for the primary analysis; that the results apply to atorvastatin 20 mg alone, not to higher doses or other statins; that two-month periods may have been insufficient for some patients; and that creatine kinase was not measured in those who withdrew. So the finding is strong in what it says and narrow in scope: a moderate dose of one common statin, at the level of the group.
But the pain is not "in your head": what the lipid specialists say
If this article stopped at the paragraph above, it would mislead. Genuine drug-caused muscle injury exists and has published numbers. In the National Lipid Association's clinical perspective on statin-associated muscle symptoms (Warden BA, Guyton JR, Kovacs AC and colleagues, Journal of Clinical Lipidology 2023;17:19–39), the writing group estimated the prevalence of SAMS overall "to be about 10% (range 5% to 25%)," then separated out what it calls pharmacological SAMS — symptoms the molecule actually causes — estimating those "to be about 1-2% (range 0.5% to 4%)," and noting that randomised trial results "have been interpreted to show that pharmacologic SAMS occur in < 1% of patients."
Within that small share, severity is graded in the document's own classification:
- Myalgia (the commonest form): "Unexplained muscle discomfort often described as 'flu-like' symptoms with normal CK level."
- Myopathy: muscle weakness, at roughly 1 in 1,000.
- Clinical rhabdomyolysis: "Myonecrosis with myoglobinuria or acute renal injury," at roughly 1 in 10,000.
And note a detail that rescues a lot of confusion: the document states plainly that "Most patients with SAMS do not have elevated CK." A normal creatine kinase result does not disprove your complaint — and it does not acquit the drug on its own either. The test is a tool for ruling out the dangerous forms, not a judge of the common one.
Are psychological factors the explanation? One study says no
It is easy to read the nocebo literature unfairly: "so it's the anxious ones who complain." A study by Peersen K, Munkhaugen J, Sverre E and colleagues (BMC Cardiovascular Disorders 2021;21:596) tested that assumption head-on, using 1,100 coronary heart disease outpatients in a cross-sectional study plus 71 in a randomised, double-blinded, placebo-controlled crossover study. The result, verbatim: "No significant differences in psychological factors (anxiety, depression, worry, insomnia, type D personality characteristics) were detected between patients with and without self-perceived SAMS, or between patients with confirmed SAMS and refuted SAMS, in the randomized study."
In exchange, the study offered something useful — a clinical discriminator. Its conclusion was that "Patients with confirmed SAMS more often present with bilateral lower muscle symptoms compared to those with refuted SAMS." The authors stated their limitations: qualitative rather than objective assessment of symptoms in the observational arm may underestimate prevalence; misclassification of refuted SAMS as confirmed cannot be excluded because of nocebo effects; and the findings may not generalise beyond the coronary populations studied.
So the balanced conclusion is this: the nocebo effect explains most of the group average; it does not acquit the drug in your particular case. Which is precisely why this cannot be settled by an article or by a feeling, but only by an organised attempt with your doctor.
What the regulator changed on the label — and what to do instead of stopping
In 2012 the U.S. Food and Drug Administration made changes to the statin label, and some of them surprise people who assume warnings are only ever added and never removed:
- Routine liver-enzyme monitoring was dropped: "FDA has determined that serious liver injury with statins is a rare adverse event and that periodic monitoring of liver enzymes is not useful."
- Memory loss and confusion: "Memory loss and confusion have been reported. The conditions are generally non-serious and reversible after stopping statin use."
- Blood sugar: "Increases in blood sugar levels have been reported," with "increased blood sugar" and "increased hemoglobin A1c levels" added to the labels as potential effects.
On blood sugar specifically there are two testimonies that do not quite agree, and it is only fair to show both. Cleveland Clinic says: "If you're already at risk for diabetes, statins can add slightly to your risk of getting it. But the benefit of statins greatly outweighs this risk." The pooled analysis in the 2022 evidence report, meanwhile, found statins "not associated with increased risk of diabetes," at a relative risk of 1.04 (0.92 to 1.19) — a confidence interval that crosses 1.0, so no difference is demonstrated. That same report also found statin therapy "not associated with significantly increased risk of serious adverse events (RR 0.97), myalgia (RR 0.98), or liver-related harms (RR 0.94)." The reasonable reading: if there is a glucose effect it is small, and probably concentrated in people already close to the threshold — which is a reason for monitoring, not for quitting.
The practical ladder: what lipid specialists recommend before giving up the drug
The National Lipid Association's advice is clear and stepwise. Once symptoms have resolved, "a statin rechallenge is recommended" — a structured second attempt. "Some patients may benefit from a washout period or drug holiday to alleviate or prevent symptoms." And there are options to change the dose or switch to a different statin.
Notice that every rung on that ladder involves two people. Not one of them is called "stop on your own and tell nobody."
And in Saudi Arabia: a decision made once and never revisited
The local gap here is not knowledge, not drug availability, and not access to a doctor. It is the nature of the decision itself: a decision to stop, taken once, in a moment of pain, and then never reopened.
In a study from National Guard Hospital in Riyadh (Suliman I, Batarfi A, Almohammadi H and colleagues, Cureus 2022;14(3):e23463), 313 statin users were surveyed. "The prevalence of muscle pain was 73.5%; 95% CI = (68.4% - 78.1%)" — all of it self-reported. Ninety-two of them (29.4%) had stopped the statin because of it, while 221 (70.6%) said they would most likely continue despite the pain.
Two reservations are required. First, the venue: Cureus lost its Web of Science indexing and impact factor when Clarivate removed it from the Master Journal List in October 2025, and this particular paper carries no published limitations section. Second, the design: a single-hospital survey, with pain reported unblinded — exactly the kind of measurement that SAMSON and StatinWISE showed mixes nocebo in with drug. So 73.5% cannot be read as a rate of drug-caused injury, nor as a national figure. It can be read as a direction, and read alongside the other number: roughly three in ten stopped a medicine that had been prescribed to them on the basis of a calculated risk.
The irony is that the two blinded trials report that half of SAMSON's participants and two thirds of those finishing StatinWISE went back, or intended to — after seeing their own result. What is missing, in other words, is not persuasion. It is a test.
Five steps to start with tomorrow
- Do not stop the drug on your own. Call your doctor or pharmacist first. Stopping silently is the one step that cannot be corrected later, because nobody knows it happened.
- Write the symptoms down with dates. When they started, where exactly, and whether they are on both sides and in the lower limbs — which, per Peersen and colleagues, is the signature of confirmed symptoms.
- Ask about a rechallenge. "Could we try pausing and restarting, or a lower dose, or a different statin?" is an entirely legitimate question, and it is what the specialists recommend by name.
- Ask for your risk in absolute terms. "How much does this drug lower my 10-year risk?" turns the argument from "are statins good or bad" into a decision that is actually about you.
- Tell every clinician everything you take, supplements and herbal products included. Some interact, and some symptoms blamed on a statin come from somewhere else entirely.
Who should be especially careful?
- Anyone with genuine muscle weakness — not just aching — or dark-coloured urine or sudden severe fatigue. These call for urgent medical contact, not a wait-and-see.
- Anyone on multiple medicines, or with known liver or kidney disease, since the chance of drug interactions rises with certain statins in particular.
- Anyone who is pregnant, breastfeeding, or planning a pregnancy: this is settled with a doctor before anything else.
- Anyone 76 or older: the Task Force rates the primary-prevention evidence as insufficient, which makes the decision an individual one.
In all of these, the decision belongs to your treating doctor, with your whole file in front of them — not to an article.
Where does Bakery 8 stand on this?
We will say it plainly, because from our side it is the most important sentence in this article: there is not a single product on our shelf that replaces a medicine your doctor prescribed. Neither our bread nor anyone else's lowers your cardiovascular risk by the margin a statin lowers it in someone who genuinely needs one. There is no loaf that "opens arteries" and no granola that "cleans out cholesterol." If your diet has improved, that is a real achievement — but it is not permission to stop a drug, and it is not a substitute for going back to whoever prescribed it.
And a second concession at our own expense: "sugar-free," "keto," and "gluten-free" are descriptions of a formulation, not promises about what it will do to your lipid panel. We commit to never marketing any product of ours as cholesterol-lowering or "artery-friendly."
The role we can honestly play is smaller and clearer: making the everyday choice easier. Samoli and cloud bread stand in for a white roll at a breakfast that repeats every single day, and keto granola is a no-added-sugar breakfast option that pairs well with nuts or plain yoghurt. If you want to go further into the dietary picture, we have written about what actually separates the three different omega-3 molecules. Food builds the foundation; medicine — in the people who need it — does something food does not do.
Frequently asked questions
Does this mean statins never cause muscle aches?
No. They do cause them, but far less often than they are blamed. The National Lipid Association put pharmacological muscle symptoms at about 1–2% (range 0.5–4%), and under 1% in randomised trials, while observational studies attribute complaints to statins at rates reaching 25%. The gap between those figures is what blinding measures.
What does SAMSON's "nocebo ratio of 0.90" actually mean?
It means nine tenths of the symptom intensity recorded during statin months was also recorded during placebo months. The symptoms were real and measured, but their dominant source was taking a tablet and expecting an effect, rather than the drug molecule itself.
I stopped my statin years ago because of pain. Is it worth trying again?
That is a question for your doctor rather than one to answer here. What we do know is that half of SAMSON's participants were back on a statin at six months, and two thirds of those finishing StatinWISE intended to restart — and every one of them had stopped because of symptoms. The National Lipid Association recommends rechallenge after symptoms resolve, by name.
Can diet replace a statin?
Diet lowers cholesterol and lowers risk, and it is a foundation nothing replaces. But it does not produce the size of reduction a statin produces in someone whose risk has been calculated and for whom the drug was prescribed. Stopping a medicine is a medical decision, made with the person who prescribed it and based on your numbers — not on an improvement in your eating alone.
References
- Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment (SAMSON). Journal of the American College of Cardiology. 2021;78(12):1210–1222. doi:10.1016/j.jacc.2021.07.022
- Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials (StatinWISE). BMJ. 2021;372:n135. doi:10.1136/bmj.n135
- Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. Journal of Clinical Lipidology. 2023;17:19–39.
- Chou R, Cantor A, Dana T, Wagner J, Ahmed A, Fu R, Ferencik M. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 219. February 2022.
- U.S. Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication — Recommendation Statement. 23 August 2022.
- Peersen K, Munkhaugen J, Sverre E, Kristiansen O, Fagerland M, Vethe NT, et al. Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC Cardiovascular Disorders. 2021;21:596. doi:10.1186/s12872-021-02422-7
- U.S. Food and Drug Administration. Cholesterol-lowering drugs get labeling changes (statin safety label changes, 2012).
- Cleveland Clinic. Statins — treatments and procedures.
- Harvard Health Publishing. Statin side effect could be due to the nocebo effect.
- Suliman I, Batarfi A, Almohammadi H, et al. Prevalence of Self-Reported Muscle Pain Among Statin Users From National Guard Hospital, Riyadh. Cureus. 2022;14(3):e23463. doi:10.7759/cureus.23463
Related keywords
statins and muscle aches · statin side effects · atorvastatin · nocebo effect · stopping cholesterol medication · statin rechallenge · creatine kinase · rhabdomyolysis · 10-year cardiovascular risk · Bakery 8, Riyadh, Saudi Arabia